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Cl1apter 1 
General Goal 
Biotechnology, the practical use of biologi-
cal knowledge, is of enormous importance to 
the industrialised· world and indeed to the 
whole of mankind. Bioinformatics, the use 
of computers and information technology in 
bio-research, is similarly increasingly impor-
tant with virtually all areas of biotechnology 
relying, to a greater or lesser degree, on this 
combination of information and technology. 
Bioinformatics is international; results and 
advances are recorded all over the world and 
Europe must and does cooperate in this inter-
national field. To continue to do so she must 
have resources that can be committed to in-
ternational activities as there are signs that 
international cooperation is breaking down. 
One reason for this is that the public/private 
financing structures for biotechnology infor-
mation and bioinformatics differ between the 
USA, Japan and Europe. This is leading to 
confusion and competition where clarity and 
cooperation are required. 
The USA also appears to be developing a 
national policy in which international partic-
ipation is questioned. At the same time the 
USA sells its own, generally subsidised, infor-
mation services abroad, undermining the lo-
cal (usually commercial) services and creating 
a situation where European and other users 
are becoming increasingly dependent upon the 
USA for relevant scientific information. This, 
1 
especially if restrictive practices were later 
introduced, such as are being mentioned at 
present, would have far-reaching negative con-
sequences for academic and industrial research 
and the information industry in Europe. 
Europe therefore needs plans to safeguard 
access and services in this area and to com-
pete and cooperate with the other interna-
tional players. The best way to do this is to 
produce relevant data services that can both 
support the European need and be integrated 
with similar projects from America and else-
where to prepare truly international systems. 
The goal of this project is thus The De-
velopment of a Strategy for European 
Biotechnology Information Infrastruc-
ture. This should be both durable and flexi-
ble, so it can change in line with the evolution 
of the field, and guide both the Commission 
of the European Communities ( CEC) and na-
tional organisations in decisions relating to the 
development and support of activities in the 
area of biotechnology information and bioin-
formatics. 
Cl1apter 2 
Methodologies 
This study has been instigated and managed 
by The Confederation of European Chemical 
Industries (CEFIC) in association with a con-
sortium of scientific publishers (Derwent, El-
sevier Science Publishers and Springer) with 
financial support from the CEC. 
This report of the research phase is based 
upon a series of interviews with scientists, 
Research and Development managers and 
information professionals in industrial and 
academic institutes in the USA, Canada, 
France, the UK, FRG, Italy, The Netherlands, 
Switzerland and Belgium. Additionally, ques-
tionnaires were sent to professional end-users 
and information professionals in all the Euro-
pean Community countries.1 
Detailed discussions with database produc-
ers (including EMBL, GenBank, PIR, HDB, 
MSDN, MINE, 1'1EDLINE, EMBASE, CABI 
and BEST)2 and database hosts (DIMDI, 
DataStar, SEQNET, and BIKE) have taken 
place and opinions and evidence taken from 
library groups and networking organisations 
such as RARE. Visits to congresses and meet-
ings were made and the relevant recent publi-
cations were also examined to follow interna-
tional considerations such as Japan's attitude 
1 See appendix 1 for the questionnaire and response 
coverage; a full analysis of the results will be presented 
in the final report). 
2 A glossary of acronyms is provided in appendix 2 
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to this subject. 
Fuller recommendations, with plans for the 
implementation of a number of policies, will 
follow in a final report to be produced this 
summer. 
Chapter 3 
Scope and Priorities 
Our, as yet incomplete, survey of databases 
relevant to biotechnology shows a wide 
variety of factual, bibliographic, collec-
tions/repositories and directory databases. 1 
The fact that the nucleic acid sequence 
databases are the foundation for many other 
types of database, such as protein sequences 
( so far as these are determined by interpre-
tating the DNA code rather than the direct 
biochemical protein sequence), and the size of 
the current international effort on the human 
and other genome projects, means that most 
emphasis and interest of people in the field 
is presently concentrated on the maintenance 
and development of nucleotide and protein se-
quence databases and the software required to 
utilise and interpret this information to the 
full. 
In addition, the need for a comprehen-
sive bibliographic database, linking the vari-
ous factual and other similar services through 
a searchable record, is obvious. 
Both these represent "hard" or "perma-
nent" data - information that can al ways be 
referred to - rather than the more transient 
data found in directories etc. 
The recommendations concerning data 
banks therefore concentrate on the se-
quence and bibliographic databanks al-
1 this list will be published with the final report. 
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though it is clear that one can extrapolate 
from these findings to other areas. 
Equally important is easy, secure, and 
cost efficient access via networks to 
databanks in these areas. European users, 
through Reseaux Associes pour la Recherche 
Europeenne (RARE), are looking at many 
such specialised needs but the biotechnology 
community is already developing dedicated 
services to facilitate the use of the above types 
of data; these have also been examined. 
Chapter 4 
The situation in the USA and 
relation to Europe Japan in 
The USA has made a firm commitment to 
biotechnology information and has, in the re-
cent past, developed far-reaching bioinformat-
ics policies and funded these in a coordinated, 
long term, manner. Many US agencies and 
government departments are involved but the 
commitment to this policy is perhaps best 
characterised by the establishment of a ded-
icated centre to this subject - the National 
Center for Biotechnology Information (NCBI), 
which is closely allied to the National Library 
of Medicine (NLM) of the National Institutes 
of Health (NIH). 
The US, and other national governments, 
are looking closely at the resources needed for 
the mapping and sequencing of the human and 
other genomes. This effort will result in a se-
ries of international sequence and related non-
commercial databases. 
American public funding in this region is 
large. The NCBI alone had a budget of $8 mil-
lion for 1989 and the NIH had reserved $27.6 
/ million for Human Genome work. The Bush 
administration has asked for $128 million for 
the entire Human Genome project in 1990 but 
other estimates indicate that total US Federal 
spending in this area will be $200 million a 
year leading to a total budget of around $3 bil-
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lion. Estimates are that the final budget for in-
formation services within the Human Genome 
project will be in the order of $30 million per 
year at the height of that project. 
This programme will give other areas of 
biotechnology a great impulse as the genome 
activities will stimulate the development and 
use of parallel programmes such as other 
nucleic acid sequence and genetic mapping 
projects and protein structure and function ac-
tivities. 
There are also a number of Human Genome 
projects in Europe which will stimulate bioin-
formatics as well as biological research . The 
UK has just begun a major initiative where 
informatics and education will play a cen-
tral role. The European Community will also 
have its Human Genome Analysis Programme. 
This, too, while not concentrating on sequenc-
ing per se, will provide a great deal of data 
that will find its way into specific and gen-
eral databases. Firm arrangements for merg-
ing this material with other international pro-
grammes are required. 
The present nucleic acid sequence databases 
(normally referred to as GenBank/EMBL) 
are built from international inputs de-
rived, presently, from Europe's EMBL ( 45%), 
Japan's DDBJ (5%), and the US Los Alamos 
team (50%). IPIR, the international cooper-
ative of the PIR project, is similarly built up 
by the Max Planck Institute for Protein Se-
quences at Martinsried (MIPS) supplying 35% 
of PIR data, the balance being American 50% 
and Japanese 15%. 
This international coverage is achieved in 
a variety of ways. EMBL and Los Alamos 
have divided the source literature between 
them, they exchange the collected data be-
tween themselves but produce two separate 
databases in slightly different formats. PIR is 
one database and receives input from various 
European, Japanese and American sources. 
As part of the streamlining taking place in 
bioinformatics in the USA the N CBI is tak-
ing steps to take over the production of the 
American sequence database GenBank from 
Los Alamos National Laboratory, and may 
well play a far greater role in the funding and 
production of the American side of the Protein 
Identification Resource (PIR) currently pro-
duced by the National Biomedical Research 
Foundation (NBRF). While this might well aid 
the American effort it is causing confusion in 
Europe. 
The NCBI plans envisage using MEDLINE 
to identify those articles with relevant infor-
mation for the specific databases. In principle 
this means the NCBI will cover all the litera-
ture ( although there are many indications that 
using MEDLINE alone will not be sufficient to 
locate all the required primary articles). These 
moves could have far-reaching consequences 
for the international nature of these projects; 
and others. If the Americans are covering "the 
literature", in fact the relatively easy to locate, 
central core literature, then the other centres 
will be left with collecting the more difficult to 
locate and therefore more expensive peripheral 
information if complete international projects 
are to be built. No real international thought 
appears to have been given to this difficulty 
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and so no clear lines for future collaboration 
been properly debated. Furthermore, there is 
no clear-cut authority in Europe to negotiate 
with the NCBI on these matters. 
International science recognised the need 
for comprehensive and mutually supportive 
databases some years ago and CODATA, the 
Committee on Data for Science and Technol-
ogy of the International Council for Scientific 
Unions, planned the Hybridoma Data Bank 
(HDB) as a collaborative venture with Eu-
rope, the USA, and Japan each producing rel-
evant data from their region and exchanging 
this via a central accreditation centre. The 
nodes then receive a collated tape back for lo-
cal use and exploitation and, in this way, pro-
duce a database without a dominant owner or 
exploitant. 
Each node is financed by national or re-
gional grants but the European node, in 1989 
supported by CEC and national moneys, has 
to recoup as much expenditure as possible 
through direct sales of the data. However, as 
neither of the other partners is in the same 
position and both can sell, or even distribute 
free, via electronic means, the same file into 
Europe, the future of the European node is 
threatened; there is little evidence that Euro-
pean users, while finding the idea of American 
dominance undesirable, are actually willing to 
pay more for the same information or service. 
We therefore have a "financing conundrum" 
where the funding partners apply different 
rules to the participants and where it is in-
creasingly difficult for European partners to 
gain revenues from their exploitation of any 
joint file. This difference in funding method-
ology could have far-reaching consequences for 
Europe's role in international database activi-
ties. 
Thus neither of these models offers, at the 
moment, long-term structures for the prepara-
tion of international databases. 
Bibliographic databases have tradition-
ally been used to locate the relevant pri-
mary article. Europe has many biotechnology-
relevant commercial services, as does the USA, 
but the Americans also have the MEDLINE 
series of databases produced by the NLM with 
grants from the NIH. This subsidised prod-
uct has long threatened the commercially pro-
duced, non-subsidised, European files but, in-
creasingly, such bibliographic databases are 
gaining another role as they will be used to 
identify the relevant primary articles for up-
take into such specialised data collections as 
the nucleic acid sequence databases or PIR or 
the HDB. 
This is part of the basis for the NCBI taking 
over the American sequence databank build-
ing activities: they will identify the relevant 
papers by scanning MEDLINE. MEDLINE 
will then probably be further integrated/ cross-
referred to a number of other databases in the 
future, to serve as the pivotal point for US 
biotechnology and biomedical data services. 
This will further undermine European bioin-
formatics. Due to the NIH subsidies, MED-
LINE has become the first choice bibliographic 
biomedical database world-wide; but it does 
not always satisfy European needs and increas-
ingly cannot cover all the relevant and impor-
tant European primary information sources. 
These moves further threaten European bibli-
ographic services by highlighting MEDLINE's 
central gateway role and mean that European 
research results, published in non-MEDLINE-
abstracted journals, will be lost from the 
MEDLINE-derived databanks. This, in turn, 
could lead to the better research papers mi-
grating from those European primary journals 
not abstracted in MEDLINE to their Ameri-
can counterparts. It will also damage interna-
tional bioinformatics, as the completeness of 
the various activities will be threatened. 
All these services increasingly use net-
works. The NLM is actively developing its 
own telecommunications network so that users 
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can reach various databases. BIONET, a non-
profit resource run for the scientific commu-
nity, funded through the Research Resources 
Division of the NIH, was, until recently, the 
main network for sequence-related work and 
offered international access to international 
destinations such as GENBANK, EMBL, PIR, 
SWISS-PROT etc., as well as offering mail and 
Bulletin Board services. The funding for this 
is being stopped and the service will, presum-
ably, be replaced by a presently, American, 
NIH/NLM alternative. 
A large majority of European scientists, 
from all parts of R&D, want a common 
telecommunications network. Most academics 
presently use their own national academic net-
work and these are interlinked through EARN 
in Europe and BITNET in the USA. Techni-
cal improvements are required but progress in 
this direction is felt to be slow and, in the ab-
sence of a common service, we are seeing the 
emergence of a number of subject-defined net-
works. 
One example concerns the European se-
quence area which has just begun to be served 
by EMBnet, a system linking the EMBL Data 
Library with a number of national/regional 
and industrial users. This service allows the 
peripheral nodes to download a nightly update 
of new nucleic acid sequence data. These pe-
ripheral nodes are increasingly carrying the re-
quired software to handle the EMBL and other 
related files and EMBnet is developing into an 
integrated service with two-way communica-
tion between the collating centre and periph-
erals with their specific needs. It is able to 
interact with many other similar services. 
Some peripheral nodes reached via this and 
other networks, are serving a national func-
tion. The Centre Inter Universitaire de Traite-
ment de I 'Information Banques de Donnees 
Biomedicales (CITI-2) at the University of 
Paris offers users current awareness services 
and the opportunity of entering sequences for 
'I 
I 
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local checking before submission to EMBL. 
SEQNET (Sequence Network Dares bury Lab-
oratory UK) offers similar services and access 
to a number of databanks (e.g. EMBL, GEN-
BANK, PIR, SWISS-PROT, Brookhaven). 
The European Human Genome Analysis Pro-
gramme is planning a similar service to EMB-
net and it is clearly advisable that these sim-
ilar services be integrated and mutually sup-
portive. 
Other, non sequence-related, international 
communication networks are developing to im-
prove communication and service among bi-
ologists. CODATA has established an elec-
tronic mail service on the commercial Dialcom 
service which offers users access to a variety 
of culture collection directories and bulletin 
boards; the Microbial Strain Data Network 
(MSDN) is also available on Telecom Gold (the 
UK owner of Dialcom) and offers access to a 
variety of culture collections and directories. 
In conclusion Europe is in no way lagging 
behind the USA in the intellectual or basic 
technical expertise required in individual ar-
eas. However, bioinformatics in the USA is 
more centralised with at least the NCBI of-
fering a focal point for research and develop-
ment and the subject enjoys a greater polit-
ical commitment. It has a firm financial ba-
sis through continuous funding while, in con-
trast, Europe has no central policy and lacks 
long-term structures on which funding can be 
based. 1 
1 Examples include the fact that the European node 
of the international Hybridoma Databank (HOB) re-
quires 150,000 ecu from public money in 1990 to con-
tinue its role in this project but there is no "open bud-
get" to provide this and the team are being forced 
to look for research-based grants to continue what is 
really an infrastructure task. The EMBL Data Li-
brary has recently also had to be temporarily "res-
cued" by last minute injections of additional money 
from the CEC above the continuous support from the 
European Molecular Biology Laboratory. The lack of 
infrastructure money means that this vital service is 
being funded on research criteria. 
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This lack of continuity certainly restricts the 
development of new data services and Euro-
pean centres of excellence. The difficulty of 
finding money and the lack of even medium-
term security makes it difficult to develop new 
services against an already highly uncertain 
and dynamic background. This is undermin-
ing the moral and long-term commitment of 
the scientists involved and is threatening Eu-
rope's present position of near parity in terms 
of data input, thereby weakening Europe's in-
fluence on international biotechnology infor-
mation activities. These weaknesses will lead, 
in turn, to an increasing dependence on Ameri-
can data services and a further chain of events 
ending in renewed calls in Senate, Congress 
and among industrial and even certain aca-
demic groups to restrict access to biotechnol-
ogy information to American users only. 
Certainly most interviewed scientists feel 
there is room for a lot of improvement in Eu-
rope and there is a general realisation among 
the leading researchers that America is pur-
chasing its way into a potentially dominant po-
sition by better funding and by "buying away" 
key European staff. Few long-term bioinfor-
matics recruits from America to Europe can 
be found but many leading researchers have 
crossed the Atlantic from Europe to develop 
bioinformatics projects. This trend, and the 
precarious base on which European bioinfor-
matics is currently based, is not generally 
recognised by European users who are happy 
to receive American subsidised material and 
even wonder why the (non-supported) Euro-
pean material is so expensive. However, when 
the potential dangers of restricted or delayed 
access are explained, European academic and 
industrial users regard the situation as being 
highly undesirable. 
Chapter 5 
European User Needs 
All interested parties agree that the 
biotechnology-relevant databases should be 
open to the international research world. 
Similarly, all scientific users of basic nucleic 
acid sequence and related data feel that the 
basic scientific data is essential as a research 
tool and that this must be available without 
restriction of access and therefore funded from 
public money. This is vehemently the case 
among academics who are very concerned lest 
European services become wholly commercial 
although scientists in industry are more will-
ing to see such services funded from private 
sources. 
There is a complete rejection of any system 
that will require scientists to pay for raw, un-
manipulated, data while they themselves are 
submitting such data to the same database(s) 
without remuneration. The intensity of use 
of these databases is, moreover, directly pro-
portional to completeness and timeliness; it 
is therefore essential that an infrastructure be 
supplied that allows easy and cheap access to 
the basic, raw, material. 
This raw data can be handled only with 
specialised software. A majority of correspon-
dents feel that an European software clearing 
house is required. 
Users increasingly require more than one 
source of information. Services such as In-
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tegrated Sequences and Structure (ISIS - a 
protein structure database product produced 
in the UK), analyse data from several basic 
databases - in the case of ISIS, seven. Such 
projects are highly specialised and require de-
velopment investment which, on most occa-
sions, cannot be recouped according to normal 
commercial rules. There is therefore the need 
for a combination of public and private fund-
ing in this area - at least while it is evolving. 
There are many specialised data services de-
rived from the original published article. This 
implies a need for basic data that can be used 
by specific centres and/ or services to provide 
added value products. Some value is added 
merely by combining different types of data to-
gether in a suitable format and most if not all 
factual data must be cross-referenced back to 
other forms of information (such as the pri-
mary article, or the relevant microbial strain 
or cell line). There is an acceptance that such 
"added value" can be charged for . 
Europe would benefit from establishing a 
series of inter-connected information centres 
with certain, basic or core, databases main-
taining a global coverage of the specific data in 
its most simple form. Other databases/centres 
would take this data, adding value in the form 
of better annotation or other improvements. 
The "basic services" will need to collect and 
correlate data from all international sources 
and so must ensure that they work in associa-
tion with other similar services. (An example 
could be a central depository of nucleic acid se-
quence data with basic annotation where other 
more specialised peripheral centres might "add 
value" by adding specific annotation.) 
It seems likely that the need for the more 
specialised services will be handled within Eu-
rope on subject specific or national/regional 
data services ( e.g. a databank of human 
genome sequences for all Europe, or a na-
tional centre satisfying pre-market-researched 
database and service needs such as SEQNET 
at Dares bury in the UK). It is also essen-
tial that such European services are integrated 
with other international services; ultimately 
scientific information needs to be as exhaus-
tive as possible and the best way to achieve 
this is through international collaboration. 
Training and "HELP" services are few 
and difficult to find. Very few academics have 
been formally trained in bioinformatics and 
only the larger industrial companies appear to 
be able to concentrate on the proper training 
of staff. One or more European centres spe-
cialising in a particular aspect of bioinformat-
ics could be considered ( this could be com-
bined with one central service or with a soft-
ware centre). National language services, or at 
least Help and Advice Centres, are also needed 
but there is a totally overwhelming insistence 
that English be used as the bioinformatics lan-
guage. Any national service should be linked 
to regional or national nodes of networks es-
tablished to service either local markets or to 
regional scientific or medical libraries if they 
exist. Such services are especially needed by 
smaller academic and industrial centres who 
lack the specialised staff and resources needed 
to use the increasingly sophisticated informa-
tion technology products. 
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Industry requires the same data and 
services as academia. Certain companies 
also require a high degree of security with re-
gard to what they are searching for and on. 
Thus Europe must offer adequate stand-alone 
as well as online services; and must allow ac-
cess to the various international sources on 
commercial as well as academic networks. 
Chapter 6 
Conclusions and Initial 
Recommendations - Towards a 
European Bioinformatics 
Strategy 
There is no clearcut European policy in 
bioinformatics although Europe has a num-
ber of national and international activities 
which, together, produce an impressive total. 
A number of European national government 
initiatives are under way, especially in the 
FRG and UK. BICEPS, funded by the Euro-
pean Commission through DGs XII and XIII, 
contributed to bioinformatics elements in the 
five year "Biotechnology Action Programme" 
(BAP) which are being subsequently further 
developed in BRIDGE; and to the launching of 
the Advanced Informatics in Medicine (AIM) 
programme. 
Europe also has many excellent and rele-
vant commercial products that, with the cor-
rect stimulus, could be used alongside publicly 
funded files for the further good of the total 
market. 
All these projects and programmes can and 
should be better coordinated and should be 
brought under on~ strategy so that they sup-
port each other. 
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This is especially the case where databases 
were/are developed as an integral part of a 
research project by specialist teams who com-
bine the scientific and computing expertise re-
quired. These are therefore often institute-
bound but bioinformatics is too important for 
it to be subject to the uncertainties of short-
term research grants or the goodwill of indi-
vidual institute policies. Essential bioinforma-
tion services should be placed in institution-
independent structures and controlled and fi-
nanced by the CEC in association with other 
relevant European and national funding agen-
cies. 
A coordinated framework, within which the 
present and future stand-alone projects can 
be managed and disseminated, is therefore re-
quired. Such an European strategy should be 
based on a willingness to establish standards 
and protocols for collaboration on an interna-
tion~d scale. 
In this regard two passages from the June 
1989 Report of the Framework Programme 
Review Board 1 seem worthy of quotation. 
Fragmentation of the European 
research environment is paralleled 
by fragmentation of research poli-
cies and ensuing lack of coherence in 
long range strategic objectives for re-
search, especially in those areas that 
can benefit from large scale coopera-
tion in planning. 
Existing European cooperation in 
science and technology adopting vari-
able geometry (under, for example, 
EUREKA, EMBO, ... ESA, ESF-
networks, etc.) should not be re-
placed, absorbed or duplicated by 
Commission sponsored programmes. 
Synergistic relationships should be 
built up between such programmes 
and the community R&D effort on 
a case by case consideration of 
the most suitable arrangements and 
need. 
Bioinformatics provides such a focal area as 
it is central to a large number of European re-
search activities in the strategically important 
life sciences and technology market. 
The CEC, seen against the total of all the 
European national programmes, might not 
play a dominant role in this area but it can and 
should play the essential position of coordi-
nator and stimulator, providing the continued 
technical, legal and financial infrastructure as 
well as specialised services required. By in-
frastructure we mean the technical ( e.g. net-
works) and basic scientific information ser-
vices (such as a central bibliographic file) upon 
which other, sectoral, data services can be 
built ( i.e. areas of specific scientific interest). 
1prepared for Vice-President Pandolfi, The Com-
mission of the European Communities, by Pierre 
Aigrain, Sir Geoffrey Allen, Eduardo De Arantes E 
Oliveira, Umberto Colombo and Hubert Markl 
In doing this the Commission should ensure 
that Europe as a whole benefits from the con-
stituent efforts in this area. Both DG XII and 
DG XIII should be involved but should com-
plement rather than compete with each other. 
The CEC should further use its influence 
to ensure that scientific information remains 
freely accessible and, wherever possible, as 
part of a truly international service. 
Bibliographic Databases 
The bibliographic database remains the key 
source to locate the original article and/ or in-
formation source. The Americans, and some 
European services, rely on MEDLINE but this 
does not satisfy all the European needs ( the 
coverage of European journals is not complete 
so some European work is "lost" to the sec-
ondary services). 
There is also an increasing tendency and 
need for authors to directly deposit sequence 
and other data into data banks. This data 
must not be lost from the present services. 
Steps should be taken to ensure that Europe's 
relevant services are attractive and competi-
tive so that customers are motivated to use 
them. 
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The European commercial, and relevant 
non-commercial database producers should be 
encouraged to collaborate. This could be to 
produce a common core database of cita-
tions that can be used by all database pro-
ducers to reduce duplication and cut costs 
thereby improving competitiveness while pro-
viding a core resource for academic, commer-
cial, and non-commercial services to produce 
added value databases. 
The CEC should not seek to establish an-
other central bibliographic database to sup-
port other specialist data services that would 
compete with existing systems. 
European national governments and the 
CEC should ensure that fair and legal con-
ditions are developed for the operation of all 
bibliographic and related databases in the in-
ternational market place. 
Factual databases and collections 
Many bioinformatic products originated in 
Europe ( e.g. EMBL was first to launch a nu-
cleic acid sequence databank). However, while 
start-up money can sometimes be obtained in 
Europe, usually as part of a research grant, 
continuing funding is difficult. Bioinformatics 
has to be seen in the light of cost /benefit 
rather than profit/loss economics. The loss 
of such information will mean a loss of compet-
itiveness in academic and industrial biotech-
nology; the benefits are generally widespread, 
diffuse, long-term and difficult to measure in 
identifiable commercial terms but are never-
theless great, continuing and of cummulative 
strategic importance. 
The commercial organisations cannot be ex-
pected to compete against subsidised Ameri-
can competition, and neither the academic nor 
the industrial market is willing to pay more 
for a project they can obtain almost "free" 
from the USA. Therefore European govern-
ments and/or the CEC should define respon-
sibility for providing these core services in nu-
cleic acid sequence and other basic, primary, 
databases. Given the present different grant-
ing structures between Europe and America 
and Japan this will require new funding rules 
as well as firm agreements with any future 
partners on the exploitation of publicly funded 
material. The CEC should ensure that Euro-
pean opinion on such questions as "the free 
access to scientific information" and "the ex-
change of relevant data" is coordinated and 
well presented in international negotiations. 
In principle Europe only requires one central 
collection and collation centre for basic nucleic 
acid and another for protein sequence infor-
mation ( although these tasks could be carried 
out in one centre). Current policies allow, and 
even promote, the duplication of similar ac-
tivities in these similar centres with resulting 
inefficiencies of duplication. The Nucleic Acid 
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Sequence Data Library, currently situated at 
EMBL, has a long history of innovative work. 
Their product and services are respected and 
regarded as essential and this expertise should 
therefore be maintained. MIPS is developing 
expertise in proteins and could become the Eu-
ropean centre for this area. The two centres 
should be supported but managed in such a 
way that they complement each other; there 
are insufficient funds to allow them to com-
pete. 
These core databases will supply data for 
other services but should not be seen as the 
only centres where databases in genetics and 
molecular biology can be produced. Thus spe-
cialised activities, such as annotating the Hu-
man Genome, can be delegated to other cen-
tres so long as they are in direct contact with 
the Central Data Library and ensure that Eu-
rope maintains one complete basic data set. 
The expected expansion of. data means that 
the present facilities at EMBL might become 
too cramped within the near future. Europe 
might then require a purpose built facility for 
this service. One could then examine whether 
this centre might play a coordinating, or even 
a physical, role in maintaining the various 
other bioinformatics services such as the Hy-
bridoma Databank, Carbank, l\lINE etc. 
Other specialist data services must also be 
readily available in Europe. A number of 
databases currently only available in America 
such as the Genome Database (GDB), Balti-
more, OMIM (Online Mendelian Inheritance 
in Man), Baltimore, and the Mouse Genome 
database in Jackson are further examples of 
the range of material that is required for effi-
cient research. These should be readily avail-
able in Europe. 
Certain specialised products and activities 
in the bioinformatics market ( e.g. annotated 
sequence databanks, ISIS) are still too di-
lute ( the data is thinly dispersed across the 
field) and immature for commercial exploita-
• 
tion. Yet these databanks, software applica-
tions and directories are essential for biologi-
cally based R&D. This report shows that mea-
sures are needed to guarantee the financial sta-
bility of basic services. There is also a need for 
initial financial support for services that might 
later become self-supporting, even if these are 
not research based but as long as they sup-
port the research need. The CEC should en-
sure that the present funding structures are 
changed so that infrastructure projects are 
continuously funded. 
Networks, Hosts and Software 
Sequence data bases require an efficient 
communication network to receive and dis-
tribute relevant data to national or regional 
and industrial nodes. EMBnet, linking as it 
does the EMBL Data Library to a number of 
national and industrial nodes, satisfies these 
needs in the sequence field and should be sup-
ported. This could be done by the CEC sup-
porting the central node, leaving the periph-
eral nodes to be financed by special interest, 
commercial, or national funds ( e.g. SEQNET 
in the UK). EMBnet should also be inter-
linked with other similar services so that Eu-
rope is linked by an integrated set of networks 
dealing with specific areas. 
EMBnet should not per se become the dom-
inant network. Other specific services, such 
as the MSDN, are developing and the CEC 
should encourage these various services to in-
teract and interlink so that industrial and aca-
demic users can ultimately communicate with 
each other on one European bioinformatics 
network or via interlinking gateways. The con-
tinuity of such networks is important and this 
topic will be covered in more detail in the sec-
ond report. 
The commercial database hosts have lit-
tle interest in offering bioinformatics data at 
present. National nodes, such as SEQNET, 
could offer an increasing number of relevant 
files and services especially in conjunction 
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with the commercial database producers who 
should be encouraged to produce relevant files 
to support the factual databases. 
Bioinformatics is dependent upon good soft-
ware. Europe would benefit from a central 
software clearing house that could advise and 
train academic and industrial users. 
Appendix 1 
The questionnaire was distributed by mail 
through CEFIC and various national organ-
isations. In some countries meetings with 
interested parties were organised before the 
questionnaires were distributed. All concerned 
were encouraged to distribute more copies of 
the questionnaire so that the final exact num-
ber of despatched copies is unkown; it will be 
more than 300 but probably less than 400. 
135 answers had been received by the end of 
february 1990, thus a coverage of about 35%. 
The responses were not evenly spread across 
the various countries. Belgium has been very 
active and accounts for some 35% of the total 
returned. France and Denmark returned fewer 
than expected but the FRG, Italy, Nether-
lands, UK and Switzerland all returned be-
tween 10 and 20 forms from which an accept-
able insight into the national situation and 
user needs could be assembled. 
The response from industrial companies 
(more than 40 answers) is relatively high com-
pared with the coverage of the university and 
institutional centres in Europe. 
A full analysis of the questionnaires will be 
given in the final report. 
Industry respondents 
Belgium 
Amycor, Clovis Matton, Co brew, Interna-
tional Bio Synthetics, Labofina, Plant Genet-
ics Systems, Smith Kline Biologicals, Solvay, 
UCB. 
FRG 
Bayer, BASF, Behrily Werke, Boehringer 
Mannheim, Hoechst Biologische Forschung, 
Hoechst Pharma Forschung, Hoechst Zentral 
Forschung. 
Denmark 
NOVO-Nordisk. 
France 
Rhone Poulenc Sante, CEN Saclay, Sanofic 
Elf. 
Italy 
Eniricerche, Farmitalia Carbo Erba, Merrel 
Dow Research Institute. 
The Netherlands 
AKZO Pharma, Biores/ Anglian Biotech, 
Dalton, DSM, Duphar, Gist Brocades, HBT 
Holland Biotech, Zaadunie. 
Switzerland 
Ciba-Geigy, Hoffmann La Roche, Nestle, 
Sandoz. 
The UK 
ICI Agro, ICI Pharmaceuticals, ICI Seeds, 
Beecham Pharmaceuticals, Glaxo, Nickerson 
International Seed Company. 
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Appendix 2 
AIM Advanced Informatics m Medicine, CEC Commission of the European Commu-
CEC programme. ties. 
BAP Biotechnology Action Programme of CEFIC European Council of the Association 
DG XII. of Chemical Industries. 
BEST British Expertise in Science and Tech-
nology - an expertise database listing re-
searchers and their skills. 
BICEPS Bioinformatics: Collaborative Pro-
grammes and European Strategy. 
BIKE Biotechnological Information Knot for 
Europe - a (German) information service 
maintained at GBF Braunschweig. 
BITNET the American research community 
telecommunications network, effectively 
the same as EARN. 
BRIDGE Biotechnology Research for Inno-
vation, Development and Growth in Eu-
rope. DG XII programme. 
CABI Commonwealth Agriculture Bureau 
Information database - a large database 
covering agriculture and agricultural 
biotechnology. 
CARBANK A international carbohydrate 
structures database, presently in prepa-
ration. 
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CERDIC European Centre for Research and 
Diffusion of Immunoclones. 
CODATA Committee on Data for Science 
and Technology of the !CSU. 
DDBJ DNA Database of Japan, National In-
stitute of Genetics, 1111 Yata Mishima, 
Shizuoka 411, Japan. 
DIMDI Deutsches Institut fiir Medizinische 
Dokumentation und Information. 
EARN European Academic Research Net-
work, a telecommunications network link-
ing European academic networks with 
each other and with American services. 
EMBASE Online version of the Excerpta 
Medica bibliographic database, produced 
by Excerpta Medica, a division of Elsevier 
Science Publishers, Amsterdam. 
EMBL European Molecular Laboratory, Hei-
delberg; funded by fifteen European 
member states. EMBL produces the Eu-
ropean Nucleic Acid Sequence Databank. 
EMBO European Molecular Biology Organ- MSDN Microbial Strain Data Network. An 
isation. electronic mail service connecting users 
to various culture collection and related 
EMBnet European Molecular Biology Data 
network - network connecting many uni-
versity and other computers, primarily for 
the dispersion of the EMBL data library. 
ESA European Space Agency. 
ESF European Science Federation. 
GDB the Genome Database available in Bal-
timore, USA. 
GENINFOA nucleic acid sequence database 
with pointers to other relevant databases 
produced by the NCBI. 
HDB The Hybridoma DataBank, an interna-
tional databank covering hybridomas and 
other related subjects. 
ICSU International Council for Scientific 
Unions. 
ISIS Integrated (protein) Sequences and 
Structures, produced by Leeds University, 
UK. 
JIPID Japanese International Protein Infor-
mation Database, Tokyo, Japan. 
MEDLINE The online database of MED-
LARS produced by the National Library 
of Medicine, Bethesda, USA. 
MINE Microbial Information Network in Eu-
rope. A network linking a series of culture 
and related collections across Europe. 
MIPS Max Planck Institute for Protein Se-
quence Data at Martinsried. The insti-
tute produces the European input for the 
international Protein Identification Re-
source database (PIR). 
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databases. Runs on Telecom Gold, a com-
mercial electronic mail service. 
NBRF National Biomedical Research Foun-
dation, Georgetown, Washington, USA. 
Producers of the (International) Protein 
Identification Resource database IPIR. 
N CBI National Centre for Biotechnology In-
formation, Bethesda, USA. 
NIH National Institutes of Health, Bethesda, 
USA. 
NLM National Library of Medicine of the 
NIH. 
OMIM Online Mendelian Inheritance m 
Man database, Baltimore, USA. 
PIR Protein Identification Resource ( of the 
NBRF). 
RARE Reseaux Associes pour la Recherche 
Europeene.A CEC supported team re-
searching the various telecommunication 
needs of Europea's research community. 
SEQNET (Nucleic acid based) series of 
databases carried on the SERC Daresbury 
computer (UK) and made available with 
supporting software to academic and in-
dustrial customers. A node on the EMB-
net service. 
SWISS-PROT Protein sequence database 
by Amos Bairoch, University of Geneva, 
in collaboration with the EMBL data li-
brary. 
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